Cytokinetics Inc (NASDAQ:CYTK)
CAPS Rating:
A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.
A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.
Recs
With a fair book value of $0.54 this could be a dangerous red thumb. However, seeing as the company is losing tons of money each quarter it seems unlikely that this is a poor long term pick for the gutter.